54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives

Key Takeaways Explain This Topic AI

Osteoporosis screening is recommended by the USPSTF (Grade B) for all women aged >=65 years and in postmenopausal women aged <65 years whose 10-year fracture risk equals or exceeds that of a 65-year-old white woman with no additional risk factors (FRAX 10-year major osteoporotic fracture risk >=8.4% or OST score <=1); in men, screening is considered at age >=70 or at 50-69 in the presence of risk factors such as hypogonadism or prolonged glucocorticoid use.

Dual-Energy X-ray Absorptiometry (DEXA) interprets bone mineral density using T-scores in postmenopausal women and men aged >=50 years: Normal (T-score >= -1.0), Osteopenia (T-score between -1.0 and -2.5), and Osteoporosis (T-score <= -2.5 at the lumbar spine, femoral neck, total hip, or 33% radius); in premenopausal women and men aged <50, Z-scores <= -2.0 indicate 'below expected range for age'.

A clinical diagnosis of osteoporosis is definitively established in the presence of a documented fragility fracture (fracture occurring from a fall from standing height or less, including vertebral compression, hip, or wrist fractures) regardless of the DEXA T-score.

Pharmacologic treatment is indicated per BHOF/NOF criteria for: 1) any hip or vertebral fragility fracture, 2) DEXA T-score <= -2.5, or 3) Osteopenia (T-score between -1.0 and -2.5) combined with a 10-year FRAX probability >=20% for major osteoporotic fracture (MOF) OR >=3% for hip fracture.

Oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) represent first-line antiresorptive therapy requiring strict administration instructions (empty stomach with 8 oz water, upright for 30-60 minutes) and reassessment for a 'drug holiday' after 3-5 years; denosumab (RANKL inhibitor) carries a critical warning that discontinuation causes severe rebound osteoclast activation and multiple vertebral fractures, mandating immediate transition to a bisphosphonate.

Last updated: September 2026

Bone Biology, Remodeling & Pathophysiology of Bone Loss

Bone is a metabolically dynamic, mineralized connective tissue undergoing continuous remodeling throughout adult life. Remodeling occurs in localized anatomical structures termed basic multicellular units (BMUs) , replacing old micro-damaged bone with newly synthesized matrix to maintain biomechanical strength and calcium homeostasis.

The Cellular Remodeling Cycle

Osteoclasts (Bone Resorption) :

Multinucleated giant cells derived from hematopoietic monocyte-macrophage precursors.

Osteoclasts adhere to bone surfaces via alpha-v-beta-3 integrins, forming an isolated sealing zone. They secrete hydrogen ions via an apical vacuolar H+-ATPase proton pump to dissolve hydroxyapatite ( Ca 10 [ PO 4 ] 6 [ OH ] 2 \text{Ca}_{10}[\text{PO}_4]_6[\text{OH}]_2 Ca 10 ​ [ PO 4 ​ ] 6 ​ [ OH ] 2 ​ ) and release cathepsin K to degrade type I collagen and bone matrix proteins.

Osteoblasts (Bone Formation) :

Mononuclear cells derived from mesenchymal stem cells under the regulation of the Runx2/Cbfa1 and Wnt/beta-catenin signaling pathways.

Osteoblasts synthesize and secrete osteoid (unmineralized organic matrix composed of 90% type I collagen) and coordinate subsequent mineral crystallization through alkaline phosphatase activity.

Osteocytes (The Mechanosensing Network) :

Terminally differentiated osteoblasts entrapped within calcified lacunae, forming an extensive canalicular communication network.

Osteocytes detect mechanical strain and fluid shear stress, orchestrating remodeling by modulating paracrine signals.

In the absence of mechanical loading, osteocytes secrete sclerostin (encoded by the SOST gene), which binds to LRP5/6 receptors, inhibiting Wnt/beta-catenin signaling and shutting down osteoblast bone synthesis. THE RANK / RANKL / OSTEOPROTEGERIN (OPG) AXIS

• Osteoblast / Stromal Precursors Osteoclast Precursors
• │ │
• ▼ ▼
• Expresses RANK Ligand (RANKL) ════════════════════════► RANK Receptor
• │ │
• │ [Inhibited by OPG] ▼
• ▼ Osteoclast Maturation,
• Secretes Osteoprotegerin (OPG) Activation, Survival
• (Soluble Decoy Receptor for RANKL) │
• │ ▼
• ▲ Bone Resorption & Matrix
• │ [Stimulated by Estrogen] Dissolution (Cathepsin K)
• ESTROGEN
• The Impact of Postmenopausal Estrogen Deficiency

Under normal physiological conditions, estrogen downregulates osteoclastogenesis by: (1) stimulating osteoblasts to produce osteoprotegerin (OPG) , a soluble decoy receptor that binds and neutralizes RANKL, (2) suppressing pro-inflammatory cytokines (IL-1, IL-6, TNF-α) that promote osteoclast recruitment, and (3) directly inducing osteoclast apoptosis.

At menopause, cessation of ovarian 17-beta-estradiol synthesis leads to unchecked RANKL signaling . The balance tips dramatically in favor of osteoclastic bone resorption:

Rapid phase of bone loss: 2% to 3% annual loss of trabecular bone during the first 5 to 8 years following menopause.

Architectural consequence: Trabecular plates become thinned, perforated, and disconnected, resulting in irreversible microarchitectural deterioration that markedly increases skeletal fragility out of proportion to bone density measurements alone.

Age-Related (Senile) Bone Loss : Beginning in the fourth decade, both men and women experience progressive decline in osteoblast synthetic capacity, blunted Wnt signaling, decreased dermal synthesis of vitamin D, intestinal calcium malabsorption, and secondary hyperparathyroidism, which primarily affects cortical bone thickness and porosity.

Screening Guidelines: USPSTF & National Consensus

Fragility fractures are silent until clinical trauma occurs. Universal and risk-targeted screening identifies individuals at elevated fracture risk before initial fracture presentation.

USPSTF Screening Recommendations (Grade B)

All Women Aged ≥65 Years : Routine screening for osteoporosis with Dual-Energy X-ray Absorptiometry (DEXA) of the hip and lumbar spine is recommended without requiring clinical risk scoring.

Postmenopausal Women Aged <65 Years : Screening is recommended if their calculated 10-year fracture risk equals or exceeds that of a 65-year-old white female with no additional risk factors.

This threshold corresponds to a 10-year Major Osteoporotic Fracture (MOF) probability of ≥8.4% calculated via the US FRAX tool without bone mineral density (BMD).

Alternatively, simple clinical risk assessment instruments such as the Osteoporosis Screening Tool (OST) (calculated as OST = [ Weight in kg − Age in years ] / 5 \text{OST} = [\text{Weight in kg} - \text{Age in years}] / 5 OST = [ Weight in kg − Age in years ] /5 ) can be used; an OST score ≤1 indicates high risk warranting DEXA.

Screening in Men

While the USPSTF concludes that current evidence is insufficient to assess the balance of benefits and harms of routine screening in men (Grade I), the Endocrine Society, National Osteoporosis Foundation (NOF / BHOF), and American College of Physicians (ACP) recommend:

All Men Aged ≥70 Years : Consideration of DEXA screening.

Men Aged 50 to 69 Years : DEXA screening is indicated if clinical risk factors are present:

• Prolonged systemic corticosteroid therapy (≥5 mg/day of prednisone equivalent for ≥3 months)
• Androgen deprivation therapy (ADT) for prostate cancer or primary/secondary hypogonadism
• Prior low-trauma fragility fracture
• Primary hyperparathyroidism, hyperthyroidism, or celiac disease
• History of chronic alcohol abuse (≥3 drinks daily) or heavy smoking
• Diagnostic Modalities: DEXA, T-Scores, Z-Scores & FRAX
• Dual-Energy X-ray Absorptiometry (DEXA)

DEXA is the diagnostic gold standard for measuring areal Bone Mineral Density (BMD in g/cm²). Two low-dose X-ray beams of differing energy levels pass through tissue, allowing subtraction of soft tissue attenuation from calcified bone.

Anatomical Scan Sites : Posteroanterior (PA) lumbar spine (L1–L4), femoral neck, total hip, and the 33% (distal one-third) radius of the non-dominant forearm. The distal radius is specifically evaluated when the hip or spine cannot be accurately assessed (e.g., severe degenerative osteoarthritis, severe scoliosis, bilateral hip arthroplasties) or in cases of primary hyperparathyroidism (which selectively resorbs cortical bone). T-SCORE VERSUS Z-SCORE COMPARISON

• Parameter T-Score Z-Score
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════
• Reference Pop. Young, healthy sex-matched reference Age-, sex-, and ethnicity-matched
• population at peak bone mass (age 20-29) reference population

• Target Population • Postmenopausal women • Premenopausal women
• Men aged ≥50 years • Men aged <50 years
• Children and adolescents

• WHO Diagnostic • Normal: T-score ≥ -1.0 • Within expected range for age: Z-score > -2.0
• Cutoffs • Osteopenia: -1.0 > T-score > -2.5 • Below expected range for age: Z-score ≤ -2.0
• Osteoporosis: T-score ≤ -2.5 (Prompts evaluation for secondary osteoporosis)
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════

Caution

DEGENERATIVE ARTIFACTS AT THE LUMBAR SPINE In patients over age 65, extensive degenerative disc disease, osteophytes, vertebral compression fractures, aortic calcifications, and facet joint osteoarthritis add artificial radiodense calcium within the DEXA beam path. This falsely elevates the lumbar spine T-score , masking severe osteoporosis. In such cases, the femoral neck, total hip, or 33% radius T-score provides the accurate diagnostic assessment.

Clinical Diagnosis of Osteoporosis: Fragility Fractures

Osteoporosis is a clinical diagnosis that does not rely solely on DEXA T-scores. A patient who experiences a fragility fracture (defined as a fracture sustained from low-energy trauma, such as a fall from standing height or less, excluding the skull, cervical spine, hands, feet, and ankles) has a definitive clinical diagnosis of osteoporosis regardless of DEXA T-score . Common fragility fracture sites include:

Vertebral Compression Fractures : Often clinically silent; may present as progressive loss of height (≥1.5 inches historically or ≥0.8 inches prospectively) or thoracic kyphosis ("dowager's hump").

Femoral Neck / Intertrochanteric Hip Fractures : Associated with 20% to 30% all-cause mortality within 1 year and permanent loss of independent ambulation in >50% of survivors.

Distal Radius (Colles) Fractures : Often the earliest clinical harbinger of skeletal fragility in perimenopausal women.

The FRAX Fracture Risk Assessment Tool

The WHO Fracture Risk Assessment Tool (FRAX) integrates 11 clinical risk factors with femoral neck BMD to calculate the 10-year probability of a Major Osteoporotic Fracture (MOF: composite of clinical spine, hip, forearm, or proximal humerus fracture) and the 10-year probability of Hip Fracture alone .

Incorporated Clinical Risk Factors :

• Age (40 to 90 years), sex, weight, height
• Prior fragility fracture as an adult
• Parental history of hip fracture (a powerful independent genetic predictor)
• Current cigarette smoking
• Systemic glucocorticoid exposure (≥5 mg prednisone equivalent daily for ≥3 months)
• Confirmed Rheumatoid Arthritis (the only disease explicitly weighted in FRAX)

Secondary osteoporosis etiologies (type 1 diabetes, osteogenesis imperfecta, hyperthyroidism, hypogonadism, chronic malabsorption)

• Alcohol intake ≥3 units per day
• Femoral neck BMD (optional; FRAX can calculate baseline risk without BMD for screening)
• Treatment Indications (BHOF / NOF Guidelines)

Pharmacologic intervention is indicated in postmenopausal women and men aged ≥50 years who meet any of the following four criteria:

A documented hip or vertebral fragility fracture (clinical or asymptomatic radiographic fracture).

A DEXA T-score ≤ -2.5 at the femoral neck, total hip, lumbar spine, or 33% radius.

Low bone mass ( Osteopenia : T-score between -1.0 and -2.5) AND a 10-year FRAX probability of Major Osteoporotic Fracture ≥20% .

Low bone mass ( Osteopenia : T-score between -1.0 and -2.5) AND a 10-year FRAX probability of Hip Fracture ≥3% .

Pharmacotherapy: Antiresorptive & Anabolic Agents OSTEOPOROSIS PHARMACOTHERAPY SPECTRUM

Class Drug & Route Dosing Schedule Key Clinical Considerations

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Oral Alendronate (Fosamax) 70 mg PO once weekly Take with 8 oz plain water; upright x 30 min;

Bisphosphonates Risedronate (Actonel) 35 mg PO once weekly Contraindicated if eGFR <30-35 or esophageal disease

• IV Zoledronic Acid (Reclast) 5 mg IV once yearly Acute-phase reaction (flu-like) in ~30%;
• Bisphosphonates (Infuse over ≥15 min) Pre-treat with acetaminophen; avoid if eGFR <35

RANKL Denosumab (Prolia) 60 mg SC every 6 months Safe in CKD; NO RENAL DOSE ADJUSTMENT;

Inhibitor CRITICAL: Stopping causes rebound vertebral fractures!

• PTH / PTHrP Teriparatide (Forteo) 20 mcg SC once daily Anabolic bone-builder; max 2 years lifetime;
• Analogues Abaloparatide (Tymlos) 80 mcg SC once daily Follow immediately with antiresorptive to retain bone

Sclerostin Romosozumab (Evenity) 210 mg SC once monthly Dual action: stimulates formation, inhibits resorption;

Inhibitor (2 prefilled syringes x12m) Boxed warning: Avoid if MI or stroke within 1 year

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Bisphosphonates (First-Line Antiresorptive Therapy)

Mechanism : Synthetic analogues of pyrophosphate that bind with high affinity to hydroxyapatite crystals in active bone remodeling sites. During resorption, osteoclasts endocytose the drug, which inhibits farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway. This prevents prenylation of small GTPases essential for osteoclast ruffled border maintenance, cytoskeletal organization, and survival, directly inducing osteoclast apoptosis .

Oral Administration Instructions :

Oral bioavailability of bisphosphonates is exceedingly poor (<1%). Ingesting any food, calcium, coffee, or juice completely prevents systemic absorption.

Must be taken first thing in the morning upon awakening , on an entirely empty stomach, with a full 8-ounce glass of plain tap water (not mineral water or sparkling water).

The patient must remain strictly upright (sitting upright, standing, or walking) for at least 30 minutes (60 minutes for oral ibandronate) and ingest no food, other liquids, or other oral medications for at least 30 to 60 minutes.

Contraindications :

• Esophageal disorders that delay emptying (e.g., severe achalasia, esophageal strictures)
• Inability to sit or stand upright for at least 30 minutes

Severe renal impairment: eGFR <35 mL/min for alendronate and zoledronic acid; eGFR <30 mL/min for risedronate and ibandronate

Uncorrected hypocalcemia

Intravenous Zoledronic Acid (5 mg IV annually) : Bypasses the gastrointestinal tract, ensuring 100% adherence. An acute-phase flu-like reaction (low-grade fever, arthralgias, myalgias) occurs in up to one-third of patients within 24 to 72 hours of the first infusion; incidence drops sharply with subsequent infusions. Prophylactic administration of oral acetaminophen substantially blunts symptoms.

Bisphosphonate 'Drug Holiday' Strategy :

Bisphosphonates incorporate into the skeletal matrix with a biological elimination half-life exceeding 10 years, providing sustained antiresorptive protection even after drug discontinuation.

Reassess fracture risk after 5 years of oral bisphosphonate (or 3 years of IV zoledronic acid ):

Low to Moderate Risk (T-score > -2.5 and no incident fractures): Initiate a drug holiday for 2 to 3 years. Monitor serial DEXA every 1 to 2 years and restart therapy if BMD declines significantly or a fracture occurs.

High Risk (Persistent hip T-score ≤ -2.5, advanced age, or prior hip/vertebral fracture): Continue oral therapy up to 10 years (or IV zoledronic acid up to 6 years) or consider transitioning to an anabolic agent.

Rare Adverse Effects Associated with Prolonged Suppression :

Atypical Femur Fractures (AFF) : Non-comminuted transverse or short oblique fractures located in the subtrochanteric region or femoral shaft, characterized by localized lateral cortical thickening/beaking. Patients typically report prodromal dull, aching groin or thigh pain for weeks to months before complete fracture. If prodromal thigh pain occurs, order bilateral full-length femur radiographs immediately and discontinue bisphosphonates.

Osteonecrosis of the Jaw (ONJ) : Exposed, necrotic bone in the maxillofacial region persisting for >8 weeks in patients with no history of radiation therapy. Associated with invasive dentoalveolar surgery (tooth extractions, dental implants). A comprehensive oral exam and necessary dental extractions should be completed before starting antiresorptive therapy.

2. RANK Ligand Inhibitor: Denosumab (Prolia)

Mechanism : A fully human IgG2 monoclonal antibody that binds with high affinity and specificity to RANKL , preventing it from activating RANK on osteoclast surfaces, completely shutting down osteoclast formation, function, and survival.

Dosing : 60 mg subcutaneous injection administered once every 6 months.

Renal Safety : Unlike bisphosphonates, denosumab is not cleared by the kidneys (cleared by the reticuloendothelial system); it is safe to use in chronic kidney disease, including stage 4 and 5 CKD and dialysis . However, patients with severe renal impairment are at high risk for severe, life-threatening hypocalcemia ; baseline calcium and vitamin D levels must be replete before each dose.

Caution

THE DENOSUMAB DISCONTINUATION REBOUND CATASTROPHE Denosumab does not incorporate into the bone matrix. When a dose is missed or discontinued, its inhibitory effect vanishes rapidly, triggering a massive rebound surge in osteoclastogenesis and bone turnover. Within 6 to 12 months after stopping denosumab, BMD declines rapidly to baseline or below, accompanied by a high risk of multiple spontaneous vertebral fractures (rebound vertebral fracture cascade) . Denosumab should NEVER be stopped without immediately transitioning to a bisphosphonate (e.g., initiating oral alendronate or IV zoledronic acid 6 months after the final denosumab injection) to lock in bone density gains.

3. Anabolic (Bone-Forming) Agents

Teriparatide (Forteo; recombinant human PTH 1-34) & Abaloparatide (Tymlos; synthetic PTHrP 1-34 analogue) :

Intermittent daily subcutaneous pulse administration preferentially stimulates osteoblast bone formation over osteoclast resorption, increasing trabecular bone volume and cortical thickness.

Indicated for patients with very high fracture risk (e.g., T-score ≤ -3.0, multiple prior fragility fractures, or failure/fractures on antiresorptive therapy).

Limited to a maximum cumulative duration of 2 years (24 months) in a patient's lifetime. When the 2-year anabolic course is completed, the patient MUST immediately be transitioned to an antiresorptive agent (bisphosphonate or denosumab); otherwise, newly formed mineralized bone is rapidly resorbed.

Contraindicated in patients with Paget's disease of bone, unexplained alkaline phosphatase elevation, prior external beam radiation therapy involving the skeleton, bone metastases, or primary hyperparathyroidism.

Romosozumab (Evenity; Sclerostin Inhibitor) :

Monoclonal antibody that neutralizes sclerostin, producing a dual effect: strongly stimulates bone formation while simultaneously decreasing bone resorption .

Administered as 210 mg SC monthly (two 105 mg injections) for exactly 12 months, followed by an antiresorptive agent.

FDA Boxed Warning : Romosozumab increases the risk of myocardial infarction, stroke, and cardiovascular death . It must NOT be initiated in patients who have experienced a myocardial infarction or stroke within the preceding year .

Lifestyle Counseling, Calcium, Vitamin D & Fall Prevention

Elemental Calcium Requirements :

1,000 mg daily for men aged 50 to 70 years.

1,200 mg daily for women aged ≥51 years and men aged ≥71 years.

Dietary Preferred : Dietary calcium (dairy products, fortified plant milks, canned salmon/sardines with bones, dark leafy greens) is the preferred source. High-dose calcium supplements (boluses >500 mg at once) may elevate transient serum calcium spikes, which have been implicated in nephrolithiasis and vascular calcification.

Vitamin D Requirements :

800 to 1,000 IU daily of Cholecalciferol (Vitamin D3) for adults aged ≥50 years, targeting a serum 25-hydroxyvitamin D level of ≥30 ng/mL (75 nmol/L) .

Physical Exercise :

Regular weight-bearing exercise (e.g., brisk walking, stair climbing) and progressive resistance training improve skeletal loading, enhance balance, and maintain muscle mass (sarcopenia prevention).

Multifactorial Fall Prevention :

Over 95% of hip fractures result from a direct fall. Primary care fall risk assessment includes:

Reviewing and deprescribing fall-risk-increasing drugs (sedative-hypnotics, benzodiazepines, anticholinergics, tricyclic antidepressants, and excessive antihypertensives causing orthostatic hypotension).

Correcting visual acuity and cataracts.

Home environment hazard mitigation: removing throw rugs, improving stair lighting, installing bathroom grab bars and non-skid shower mats.

Referral to physical therapy for balance, gait, and core stability training (e.g., Tai Chi).

Loading diagram... Clinical Decision Algorithm for Osteoporosis Screening, Diagnosis, and Pharmacotherapy